Standardized PSADT calculations are crucial for timely prostate cancer treatment, potentially preventing metastasis and reducing treatment costs. Casdatifan shows promise in clear cell RCC, with a 100 ...
Phase 1 and 3 trials demonstrated improved survival rates, with new treatment strategies for EGFR-mutated NSCLC, HER2+ breast cancer, and small-cell lung cancer. AI innovations, such as the ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results